ProCE Banner Activity

CE / CME

Lessons Learned From Lockdown: Viral Hepatitis–Related Liver Disease in the COVID-19 Era

Text Module

Learn important data on the interplay of COVID-19 and viral hepatitis–related liver disease, including COVID-19 outcomes in patients with chronic liver disease (CLD) and expert guidance on clinical management, vaccination, and optimization of telemedicine for patients with CLD during the COVID-19 pandemic.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: January 10, 2022

Expiration: January 09, 2023

No longer available for credit.

Share

Faculty

Robert G. Gish

Robert G. Gish, MD

Medical Director
Complex GI and Specialty Services
California Pacific Medical Center
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Educational grants provided by:

AbbVie

Gilead Sciences, Inc.

Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for patients with viral hepatitis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Optimize care for persons with or at risk of viral hepatitis that is reflective of new challenges from the COVID-19 pandemic

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Robert G. Gish, MD

Medical Director
Complex GI and Specialty Services
California Pacific Medical Center
San Francisco, California

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Altimmune, Antios, Arrowhead, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Pfizer, Salix, Shionogi, Topography Health, Venatorx, and Viking; has served on advisory boards for Abbott, AbbVie, Altimunne, Antios, Arrowhead, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Pfizer, Salix, Shionogi, Venatorx, and Viking; and has served on data and safety monitoring boards for Altimmune, Arrowhead, CymaBay, and Durect.

Staff Disclosure

Staff

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Jennifer Swanson, MEd

Associate Managing Editor, Hematology/Oncology
Clinical Care Options, LLC

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-016-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 10, 2022, through January 09, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to enable learners to adapt their patient care strategies to continue to provide high-quality care for patients with viral hepatitis despite the impact of the COVID-19 pandemic.